Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
Harvard Bioscience (Nasdaq: HBIO) has expanded its distribution agreement with Fisher Scientific to include the United States market, building upon their existing European partnership. The expanded agreement enables Fisher Scientific to distribute Harvard Bioscience's pumps, spectrophotometers, and BTX electroporation systems throughout the U.S.
The strategic expansion gives Harvard Bioscience access to hundreds of Fisher Scientific sales representatives and their extensive U.S. distribution network. The partnership will offer both established product lines and emerging technologies, including the Mesh MEA for advanced organoid research. This collaboration aims to enhance customer experience through streamlined ordering, faster delivery, and localized support.
Harvard Bioscience (Nasdaq: HBIO) ha ampliato l'accordo di distribuzione con Fisher Scientific per includere il mercato degli Stati Uniti, facendo leva sulla loro partnership europea esistente. L'accordo ampliato consente a Fisher Scientific di distribuire i pump, spectrophotometers, e sistemi di elettroporazione BTX di Harvard Bioscience in tutto il territorio USA.
La espansione strategica dà ad Harvard Bioscience accesso a centinaia di rappresentanti di vendita di Fisher Scientific e alla loro estesa rete di distribuzione negli Stati Uniti. La partnership offrirà sia linee di prodotto consolidate sia tecnologie emergenti, inclusi Mesh MEA per la ricerca avanzata di organoidi. Questa collaborazione mira a migliorare l'esperienza del cliente attraverso un processo di ordine snello, consegna più rapida e supporto localizzato.
Harvard Bioscience (Nasdaq: HBIO) ha ampliado su acuerdo de distribución con Fisher Scientific para incluir el mercado de Estados Unidos, basándose en su ya existente asociación europea. El acuerdo ampliado permite a Fisher Scientific distribuir los bombas, espectrofotómetros y sistemas de electroporación BTX de Harvard Bioscience en todo Estados Unidos.
La expansión estratégica da a Harvard Bioscience acceso a centenas de representantes de ventas de Fisher Scientific y a su amplia red de distribución en EE. UU. La asociación ofrecerá tanto líneas de productos establecidas como tecnologías emergentes, incluyendo el Mesh MEA para la investigación avanzada de organoides. Esta colaboración tiene como objetivo mejorar la experiencia del cliente mediante un proceso de pedido simplificado, entrega más rápida y soporte localizado.
Harvard Bioscience (Nasdaq: HBIO)는 Fisher Scientific과의 유통 계약을 미국 시장으로 확대하여 기존의 유럽 파트너십을 바탕으로 확장했습니다. 확대된 계약으로 Fisher Scientific은 미국 전역에 Harvard Bioscience의 펌프, 분광광도계, BTX 전기천공 시스템을 유통하게 됩니다.
전략적 확장으로 Harvard Bioscience는 수백 명의 Fisher Scientific 판매 대리인과 그들의 광범위한 미국 유통망에 접근할 수 있게 되었습니다. 이 파트너십은 기존 제품 라인과 신기술을 모두 제공하며, 고급 오가노이드 연구를 위한 Mesh MEA를 포함합니다. 이 협력은 주문의 간소화, 더 빠른 배송, 지역 맞춤형 지원을 통해 고객 경험을 향상시키는 것을 목표로 합니다.
Harvard Bioscience (Nasdaq: HBIO) a étendu son accord de distribution avec Fisher Scientific pour inclure le marché américain, s'appuyant sur leur partenariat européen existant. Le nouvel accord permet à Fisher Scientific de distribuer les pompes, spectrophotomètres et systèmes d'électroporation BTX de Harvard Bioscience sur l'ensemble des États‑Unis.
Cette expansion stratégique donne à Harvard Bioscience accès à des centaines de représentants commerciaux de Fisher Scientific et à leur vaste réseau de distribution américain. Le partenariat proposera à la fois des gammes de produits établies et des technologies émergentes, y compris le Mesh MEA pour la recherche avancée sur les organoïdes. Cette collaboration vise à améliorer l'expérience client grâce à une commande simplifiée, une livraison plus rapide et un support localisé.
Harvard Bioscience (Nasdaq: HBIO) hat seine Vertriebsvereinbarung mit Fisher Scientific erweitert, um den US-Markt abzudecken, basierend auf ihrer bestehenden europäischen Partnerschaft. Die erweiterte Vereinbarung ermöglicht es Fisher Scientific, die Pumpen, Spektralphotometer und BTX-Elektroporationssysteme von Harvard Bioscience in den gesamten USA zu vertreiben.
Diese strategische Expansion verschafft Harvard Bioscience Zugriff auf Hunderte von Vertriebsmitarbeitern von Fisher Scientific und ihr umfangreiches Vertriebsnetz in den USA. Die Partnerschaft wird sowohl etablierte Produktlinien als auch aufkommende Technologien anbieten, darunter das Mesh MEA für fortschrittliche Organoid-Forschung. Ziel der Zusammenarbeit ist es, das Kundenerlebnis durch eine schlankere Bestellabwicklung, schnellere Lieferung und lokalen Support zu verbessern.
Harvard Bioscience (Nasdaq: HBIO) وسّعت اتفاقية التوزيع مع Fisher Scientific لتشمل السوق الأمريكية، مبنية على شراكتهما الأوروبية القائمة. تسمح الاتفاقية الموسّعة لـ Fisher Scientific بتوزيع المضخات، ومطيافيات الامتصاص، وأنظمة التحفيز الكهربائي BTX الخاصة بـ Harvard Bioscience في جميع أرجاء الولايات المتحدة.
توفر هذه التوسعة الاستراتيجية لـ Harvard Bioscience إمكانية الوصول إلى مئات من مندوبي المبيعات لدى Fisher Scientific وشبكتهم الواسعة من قنوات التوزيع في الولايات المتحدة. ستقدم الشراكة خطوط المنتجات القائمة وكذلك التقنيات الناشئة، بما في ذلك Mesh MEA لأبحاث العضيات المتقدمة. تهدف هذه التعاون إلى تحسين تجربة العملاء من خلال تبسيط الطلب، وتسليم أسرع، ودعم محلي.
Harvard Bioscience (Nasdaq: HBIO) 已将其与 Fisher Scientific 的分销协议扩展至美国市场，在现有欧洲伙伴关系的基础上进一步扩展。扩展后的协议使 Fisher Scientific 能在整个美国分销 Harvard Bioscience 的 泵、分光光度计和 BTX 电穿孔系统。
这一战略扩张使 Harvard Bioscience 能接触到 数百名 Fisher Scientific 的销售代表及其广泛的美国分销网络。该伙伴关系将提供既有的产品线和新兴技术，包括 用于高级器官培养研究的 Mesh MEA。此次合作旨在通过简化下单、加快交付和本地化支持来提升客户体验。
- Access to hundreds of Fisher Scientific sales representatives in the U.S. market
- Expanded distribution network through partnership with one of world's largest scientific suppliers
- Streamlined ordering and faster delivery capabilities for customers
- Enhanced market reach for both established products and emerging technologies
- None.
Insights
HBIO expands US market reach by partnering with Fisher Scientific, significantly enhancing distribution capabilities and sales potential.
Harvard Bioscience's expanded distribution agreement with Fisher Scientific represents a strategic channel enhancement that significantly amplifies their US market penetration capabilities. By leveraging Fisher Scientific's extensive sales network—comprising hundreds of representatives across North America—HBIO gains an established route to market that would otherwise require substantial direct investment to replicate.
The distribution arrangement specifically covers three critical product categories: pumps, spectrophotometers, and BTX electroporation systems. What's particularly valuable is the inclusion of emerging technologies like the Mesh MEA for organoid research, positioning Harvard Bioscience to accelerate market adoption of their innovation pipeline.
From a channel efficiency perspective, this agreement creates a significant procurement advantage for end customers. Scientific laboratories typically manage dozens of vendor relationships, and consolidating purchases through Fisher Scientific—one of the most established scientific suppliers—reduces administrative overhead and simplifies purchasing workflows for lab managers and procurement departments.
The expansion from Europe to include the US market represents a logical channel evolution. Fisher Scientific's parent company, Thermo Fisher Scientific, maintains one of the most comprehensive distribution infrastructures in the life sciences sector. By first establishing effectiveness in Europe before expanding to the US, Harvard Bioscience has followed a measured approach to channel development that minimizes execution risk.
This agreement's true value lies in its potential to accelerate HBIO's market reach without corresponding increases in direct sales investment, allowing for more efficient revenue scaling across their product portfolio.
- Strategic expansion with trusted partner enhances customer reach
HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world’s largest and most trusted scientific suppliers. Under this new agreement, Fisher Scientific will now offer Harvard Bioscience pumps, spectrophotometers, and BTX electroporation systems in the United States, complementing the existing distribution agreement in Europe. This agreement provides Harvard Bioscience access to hundreds of Fisher Scientific sales representatives who will now offer customers both established product lines—such as pumps and electroporation systems—and access to emerging technologies, including the Mesh MEA (Microelectrode Array) for advanced organoid research.
This strategic expansion marks a significant milestone in Harvard Bioscience’s mission to provide researchers with high-performance, reliable instruments that accelerate scientific discovery. By leveraging Fisher Scientific’s extensive U.S. distribution network and unmatched reputation for customer service, Harvard Bioscience can now deliver even greater convenience and accessibility to its customers across North America.
“Expanding our partnership with Fisher Scientific in the U.S. is a significant step toward providing Harvard Bioscience products to all potential customers throughout the United States,” said John Duke, President & Chief Executive Officer of Harvard Bioscience. “This collaboration enhances the customer experience by providing streamlined ordering, faster delivery, and localized support through a trusted partner.”
With the expanded distribution agreement of Harvard Bioscience’s pumps, spectrophotometers, and electroporation systems to Fisher Scientific’s U.S. catalog, customers can now source a comprehensive range of precision tools from a single vendor — saving valuable time and simplifying procurement processes. The expanded availability ensures that laboratories in both academia and industry can access cutting-edge technologies with the logistical support and purchasing flexibility they expect.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at https://www.harvardbioscience.com.
Forward-Looking Statements
This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend,” “believe” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenue and gross margin, and matters relating to the Company’s ability to continue as a going concern, fund its operations, or refinance outstanding indebtedness. Forward-looking statements do not guarantee future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.
Investor Inquiries:
(508) 893-3120
investors@harvardbioscience.com
FAQ
What products will Fisher Scientific distribute for Harvard Bioscience in the US?
How does the Fisher Scientific partnership benefit Harvard Bioscience customers?
Where does Harvard Bioscience (HBIO) currently have distribution agreements with Fisher Scientific?
What is the significance of Harvard Bioscience's expanded distribution agreement?
Who is the current CEO of Harvard Bioscience (HBIO)?
